Adverse drug reactions: definitions, diagnosis, and management.

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (2004) 21.39

Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One (2009) 3.45

Adverse events following acupuncture: prospective survey of 32 000 consultations with doctors and physiotherapists. BMJ (2001) 3.29

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ (2006) 2.40

Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ (2009) 2.10

Does computerized provider order entry reduce prescribing errors for hospital inpatients? A systematic review. J Am Med Inform Assoc (2009) 2.09

Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int (2013) 2.06

Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India. Indian J Med Res (2015) 2.01

Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci (2010) 1.98

Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr (2008) 1.95

Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J (2008) 1.86

Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83

An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res (2011) 1.72

Bi- or multifunctional opioid peptide drugs. Life Sci (2009) 1.69

Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis. PLoS One (2012) 1.68

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther (2005) 1.63

Patient reports of adverse events associated with acupuncture treatment: a prospective national survey. Qual Saf Health Care (2004) 1.63

Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther (2011) 1.61

Mass drug administration for malaria. Cochrane Database Syst Rev (2013) 1.54

Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol (2012) 1.52

Provider management of and satisfaction with laboratory testing in the nursing home setting: results of a national internet-based survey. J Am Med Dir Assoc (2009) 1.52

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50

Status of documentation grading and completeness score for Indian individual case safety reports. Indian J Pharmacol (2015) 1.43

Is dermatomyositis in patients with rheumatoid arthritis induced by anti-TNF-α therapy? Clin Rheumatol (2011) 1.40

Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data. BMC Health Serv Res (2011) 1.31

Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol (2010) 1.31

Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia. Malar J (2013) 1.27

International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA. BMC Health Serv Res (2014) 1.24

Evaluating adverse drug event reporting in administrative data from emergency departments: a validation study. BMC Health Serv Res (2013) 1.23

Association of adverse drug reactions with drug-drug and drug-disease interactions in frail older outpatients. Age Ageing (2010) 1.22

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis. Indian J Pharmacol (2011) 1.16

Adverse effects of extra-articular corticosteroid injections: a systematic review. BMC Musculoskelet Disord (2010) 1.16

Health care personnel and risk of H1N1-chemoprophylaxis with oseltamivir. Indian J Pharmacol (2012) 1.14

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis (2004) 1.14

Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough? Qual Saf Health Care (2005) 1.13

Adverse drug reactions causing admission to a paediatric hospital. PLoS One (2012) 1.11

Pharmacogenetics of drug hypersensitivity. Pharmacogenomics (2010) 1.09

Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. Pan Afr Med J (2012) 1.08

Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. BMC Med (2013) 1.07

Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child (2011) 1.07

Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. Open Forum Infect Dis (2017) 1.07

The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol (2011) 1.05

Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol (2010) 1.04

Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. J Allergy Clin Immunol (2015) 1.03

Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study. PLoS One (2013) 1.02

Development and validation of a risk model for predicting adverse drug reactions in older people during hospital stay: Brighton Adverse Drug Reactions Risk (BADRI) model. PLoS One (2014) 1.02

Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inform Assoc (2014) 1.01

Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics (2010) 1.01

Drug Eruptions: An 8-year Study Including 106 Inpatients at a Dermatology Clinic in Turkey. Indian J Dermatol (2012) 1.01

An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01

Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports. J Pharmacol Pharmacother (2013) 1.01

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01

Chemotherapy-related hospitalization among community cancer center patients. Oncologist (2011) 1.00

Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol (2006) 1.00

Pharmacovigilance on twitter? Mining tweets for adverse drug reactions. AMIA Annu Symp Proc (2014) 1.00

A new approach to identify, classify and count drug-related events. Br J Clin Pharmacol (2013) 0.99

Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metab Toxicol (2009) 0.98

A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging (2014) 0.98

Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med (2014) 0.97

ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc (2013) 0.97

Assessing the performance characteristics of signals used by a clinical event monitor to detect adverse drug reactions in the nursing home. AMIA Annu Symp Proc (2008) 0.96

Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J (2005) 0.96

Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults. Br J Clin Pharmacol (2014) 0.96

Captopril-induced bilateral parotid and submandibular sialadenitis. Eur J Clin Pharmacol (2004) 0.95

Epidemiology of adverse drug reactions in europe: a review of recent observational studies. Drug Saf (2015) 0.95

Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging (2014) 0.95

Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci (2012) 0.95

Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf (2013) 0.94

Population pharmacokinetics of oral diclofenac for acute pain in children. Br J Clin Pharmacol (2008) 0.94

Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol (2001) 0.93

Drug-related problem in children with chronic kidney disease. Pediatr Nephrol (2012) 0.93

Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study. BMJ Open (2012) 0.92

The impact of China's national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces. BMC Health Serv Res (2014) 0.92

Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf (2006) 0.92

New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. Antimicrob Agents Chemother (2010) 0.92

Adverse drug reactions in older patients: an Italian observational prospective hospital study. Drug Healthc Patient Saf (2012) 0.92

Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood (2014) 0.91

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials. Invest New Drugs (2010) 0.91

Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. Eur J Clin Pharmacol (2013) 0.91

Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol (2010) 0.90

Critical gaps in the world's largest electronic medical record: Ad Hoc nursing narratives and invisible adverse drug events. AMIA Annu Symp Proc (2003) 0.90

Pregabalin-induced self-harm behavior. Indian J Pharmacol (2013) 0.90

Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol (2014) 0.89

Identifying plausible adverse drug reactions using knowledge extracted from the literature. J Biomed Inform (2014) 0.89

A case of ciprofloxacin-induced erythema multiforme. Indian J Pharmacol (2008) 0.89

Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. PLoS One (2013) 0.88

Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol (2011) 0.88

Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Br J Clin Pharmacol (2009) 0.88

The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study. BMC Geriatr (2013) 0.88

The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica. Pharm Pract (Granada) (2008) 0.88

Adverse drug reactions & their risk factors among Indian ambulatory elderly patients. Indian J Med Res (2012) 0.88

Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India. PLoS One (2014) 0.87

Capreomycin-induced optic neuritis in a case of multidrug resistant pulmonary tuberculosis. Indian J Pharmacol (2010) 0.87

Safety of benzathine penicillin for preventing congenital syphilis: a systematic review. PLoS One (2013) 0.87

Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol (2004) 0.87

DAMASCENE and Meta-Ecological Research: A Bridge Too Far. Circ Res (2014) 0.87

Prevalence and perceived preventability of self-reported adverse drug events--a population-based survey of 7099 adults. PLoS One (2013) 0.87

Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria. Wien Klin Wochenschr (2008) 0.87

Epidemiological study of cutaneous adverse drug reactions in oman. Oman Med J (2008) 0.87

Frequency of laboratory monitoring of chronic medications administered to nursing facility residents: results of a national Internet-based study. Consult Pharm (2008) 0.87

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50

Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47

Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33

Medication errors, worse than a crime. Lancet (2000) 2.24

A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24

Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07

Rare diseases and orphan drugs. Br J Clin Pharmacol (2006) 1.83

Balanced prescribing. Br J Clin Pharmacol (2006) 1.74

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60

Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56

Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44

Rational prescribing, appropriate prescribing. Br J Clin Pharmacol (2004) 1.43

Prescribing statins. Br J Clin Pharmacol (2005) 1.42

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40

Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. QJM (1996) 1.39

In defence of polypharmacy. Br J Clin Pharmacol (2004) 1.38

Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34

Digitalis intoxication. Clin Sci (Lond) (1983) 1.29

Plagiarism - please don't copy. Br J Clin Pharmacol (2007) 1.29

Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25

Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23

The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. Br J Clin Pharmacol (1979) 1.20

Clinical pharmacology--providing tools and expertise for translational medicine. Br J Clin Pharmacol (2008) 1.19

ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ (1993) 1.13

ABC of monitoring drug therapy. Lithium. BMJ (1992) 1.13

What is a clinical trial? Br J Clin Pharmacol (2004) 1.13

Drug interactions-information, education, and the British National Formulary. Br J Clin Pharmacol (2004) 1.12

Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11

Risk perception in drug therapy. Br J Clin Pharmacol (2006) 1.11

Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10

The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10

The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med (1980) 1.09

Communicating information about drug safety. BMJ (2006) 1.08

The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07

Interaction of azapropazone with phenytoin. Br Med J (Clin Res Ed) (1982) 1.06

Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet (1980) 1.05

Old drugs--new uses. Br J Clin Pharmacol (2007) 1.03

Who cares about pharmacovigilance? Eur J Clin Pharmacol (1997) 1.02

Dietary salt and hypertension: treatment and prevention. Br Med J (Clin Res Ed) (1985) 1.02

Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98

Cation transport abnormalities in vivo in untreated essential hypertension. Clin Sci (Lond) (1986) 0.98

A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. Clin Sci (Lond) (1984) 0.97

Classifying drug interactions. Br J Clin Pharmacol (2004) 0.97

Prolonged half-life of verapamil in a case of overdose: implications for therapy. Br J Clin Pharmacol (1995) 0.96

Indications for the measurement of plasma digoxin concentrations. Drugs (1983) 0.96

Inhibition of Na+/K(+)-ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. Apoptosis (2000) 0.95

Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. Br J Clin Pharmacol (1977) 0.95

Over-the-counter medicines. Br J Clin Pharmacol (2004) 0.95

Antibiotics policies in the developing world. Eur J Clin Pharmacol (1991) 0.94

Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. J Hypertens (1993) 0.94

Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med (1978) 0.94

Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol. Br J Clin Pharmacol (1980) 0.92

The NSAID roller coaster: more about rofecoxib. Br J Clin Pharmacol (2006) 0.92

ABC of monitoring drug therapy. Cyclosporin. BMJ (1992) 0.91

A sensitive high-temperature electrothermal atomic absorption analysis for Rb+ in erythrocytes and plasma of normal and hypertensive persons. Clin Chem (1985) 0.87

Drug development: more science, more education. Br J Clin Pharmacol (2005) 0.87

In vivo cation transport during short-term and long-term digoxin therapy. Br J Clin Pharmacol (1986) 0.87

Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. Br J Pharmacol (2001) 0.86

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. Gut (1992) 0.85

Metabolism of an oral tryptophan load III: effect of a pyridoxine supplement. Br J Clin Pharmacol (1980) 0.85

Sodium-lithium countertransport in erythrocytes of pregnant women. N Engl J Med (1982) 0.85

Monitoring therapy. Br J Clin Pharmacol (2005) 0.85

Medication errors: EMERGing solutions. Br J Clin Pharmacol (2009) 0.84

Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. Klin Wochenschr (1981) 0.84

National differences in publishing papers on adverse drug reactions. Br J Clin Pharmacol (2005) 0.83

Clinical pharmacology. Adverse drug interactions. Br Med J (Clin Res Ed) (1981) 0.82

Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. Br J Pharmacol (2000) 0.82

Citation classics in the British Journal of Clinical Pharmacology, 1974-2003. Br J Clin Pharmacol (2004) 0.81

Interaction of digoxin with quinine. Lancet (1981) 0.81

Increases in Na/K pump numbers in isolated human lymphocytes exposed to lithium in vitro. Reversal by myo-inositol and by inhibitors of protein kinase C and the Na/H antiport. Biochim Biophys Acta (1991) 0.81

A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole. Br J Clin Pharmacol (1989) 0.81

Measurement of cation transport in vivo in healthy volunteers after the oral administration of lithium carbonate. Clin Sci (Lond) (1989) 0.80

Evidence for altered Na+/H+ antiport activity in cultured skeletal muscle cells and vascular smooth muscle cells from the spontaneously hypertensive rat. Clin Sci (Lond) (1991) 0.80

Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol (1988) 0.80

Altered in vitro adaptive responses of lymphocyte Na+,K(+)-ATPase in patients with manic depressive psychosis. J Affect Disord (1991) 0.80

Moving about. Br J Clin Pharmacol (2005) 0.80

Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers. Br J Clin Pharmacol (1991) 0.79

Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. Br J Clin Pharmacol (1983) 0.79

Identification of system y+L as the high-affinity transporter for L-arginine in human platelets: up-regulation of L-arginine influx in uraemia. Pflugers Arch (1999) 0.79

Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na+/K+ pumps in an Epstein-Barr virus-transformed human lymphocyte cell line. Biochem Pharmacol (1992) 0.78

Laughter and MIRTH (Methodical Investigation of Risibility, Therapeutic and Harmful): narrative synthesis. BMJ (2013) 0.78

The pharmacokinetics of L-tryptophan following its intravenous and oral administration. Br J Clin Pharmacol (1985) 0.78

Metameta-analysis. Br J Clin Pharmacol (2005) 0.78

Can understanding mechanisms solve the problem of extrapolating from study to target populations (the problem of 'external validity')? J R Soc Med (2013) 0.77

Erythrocytic cation transport receptor numbers and activity in pregnancies complicated by essential hypertension and pre-eclampsia. Br Med J (Clin Res Ed) (1984) 0.77

Evidence for increased in vivo sodium-potassium pump activity and potassium efflux in skeletal muscle of spontaneously hypertensive rats. J Hypertens (1990) 0.77

The upregulation of Na+,K(+)-ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. J Affect Disord (1995) 0.76

The effect of beta 2-adrenoceptor stimulation and blockade of L-type calcium channels on in vivo Na+/H+ antiporter activity in rat skeletal muscle. Biochim Biophys Acta (1991) 0.76

Evidence for an R(+)-[(dihydroindenyl)oxy]alkanoic acid-sensitive K+/Cl- co-transporter in human platelets and its interaction with the Na+/K+/2Cl- co-transporter. Clin Sci (Lond) (1997) 0.75

Monitoring for harms of therapy. Br J Clin Pharmacol (2006) 0.75

Digoxin revisited. QJM (1998) 0.75

One hundred years of atrial fibrillation. Br J Clin Pharmacol (2005) 0.75

Adverse events in British hospitals. Retrospective case record analysis has been superseded. BMJ (2001) 0.75

Write on. Br J Clin Pharmacol (2005) 0.75

Cardiac arrhythmias: theory and practice. Br Med J (Clin Res Ed) (1985) 0.75

The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers. Br J Clin Pharmacol (1991) 0.75

Increase in Na+/K+ pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro. Br J Clin Pharmacol (1992) 0.75

Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment. Br Heart J (1989) 0.75

The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers. Br J Clin Pharmacol (1990) 0.75

NSAIDs and gut toxicity. Lancet (1994) 0.75